This study aims to investigate the real indications for low-dose tamsulosin monotherapy for initial treatment. A cross-sectional study was conducted in a total of 1643 patients with lower urinary tract symptoms (LUTS) and with initial lowdose tamsulosin. Initial pretreatment data including the International Prostate Symptoms Score (IPSS), prostate volume, and uroflowmetry data were reviewed. After 8 weeks of treatment, post-treatment IPSS and satisfaction was assessed. Logistic regression analysis was conducted to investigate the pretreatment factors influencing post-treatment satisfaction. Overall satisfaction rate with low-dose tamsulosin as an initial treatment medication was 88.7%. Multivariate analysis revealed that symptom durations, IPSS voiding score, IPSS storage score, and quality of life (QoL) were determinant factors for patient satisfaction. ROC analysis revealed that a urinary score>10 and symptom duration>3 years showed satisfaction with a sensitivity of 85.8% and 90.6%, respectively, and specificity of 43.5% and 39.8%, respectively. Whereas, ROC analysis revealed that a storage score>5 and QoL>3 showed nonsatisfaction with sensitivity of 84.2% and 39.5%, respectively, and specificity of 43.5% and 45.7%, respectively. Multivariate regression analysis demonstrated that voiding score and storage score had a significant relationship with QoL (unstandardized coefficients: 0.073, 0.145, respectively; P-value:<.001,<.001, respectively). The patient with higher storage scores and higher QoL before treatment could have a higher change of non-satisfaction. Combining treatment with anticholinergics could be considered in these patients.
Bibliographical noteFunding Information:
Availability of data and materials: All data generated or analyzed during this study are included in this published article [and its supplementary information files]. Consent for publication: Not applicable Competing interests: None declared. Ethics approval and consent to participate: Informed consent was obtained from each subject, and the study was approved by the Institutional Review Board at each center. This research was supported by the Next-generation Medical Device Development Program for Newly-Created Market of the National Research Foundation (NRF) funded by the Korean government, MSIP (No. 2015M3D5A1065926), and also by the Soonchunhyang University Research Fund.
© 2018 the Author(s). Published by Wolters Kluwer Health, Inc.
- Lower urinary tract symptoms
- Prostatic hyperplasia
ASJC Scopus subject areas